89Bio Inc.

15/11/2024 | Press release | Distributed by Public on 15/11/2024 14:04

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.